MA40882A - Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf - Google Patents

Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf

Info

Publication number
MA40882A
MA40882A MA040882A MA40882A MA40882A MA 40882 A MA40882 A MA 40882A MA 040882 A MA040882 A MA 040882A MA 40882 A MA40882 A MA 40882A MA 40882 A MA40882 A MA 40882A
Authority
MA
Morocco
Prior art keywords
binding molecules
trimer
antigen binding
tnf family
molecules including
Prior art date
Application number
MA040882A
Other languages
English (en)
Other versions
MA40882B1 (fr
Inventor
Maria Amann
Peter Bruenker
Christina Claus
Koller Claudia Ferrara
Sandra Grau-Richards
Christian Klein
Viktor Levitsky
Ekkehard Moessner
Joerg Thomas Regula
Pablo Umaña
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54695680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40882(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA40882A publication Critical patent/MA40882A/fr
Publication of MA40882B1 publication Critical patent/MA40882B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furniture Connections (AREA)
  • Connection Of Plates (AREA)

Abstract

L'invention concerne de nouvelles molécules de liaison à l'antigène comprenant un ligand trimérique de la famille du tnf comprenant (a) au moins une partie capable de se lier de manière spécifique à un antigène d'une cellule cible et (b) un premier et un second polypeptides liés l'un à l'autre par un pont disulfure, et caractérisés par le fait que le premier polypeptide comprend deux ectodomaines d'un membre de la famille des ligands du tnf ou des fragments de ce dernier, liés l'un à l'autre par un peptide lieur, et que le second polypeptide comprend un seul ectodomaine dudit membre de la famille des ligands du tnf ou un fragment de ce dernier.
MA40882A 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf MA40882B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14193260 2014-11-14
EP15183736 2015-09-03
EP15188142 2015-10-02
PCT/EP2015/076528 WO2016075278A1 (fr) 2014-11-14 2015-11-13 Molécules de liaison à l'antigène comprenant un ligand trimèrique de la famille du tnf

Publications (2)

Publication Number Publication Date
MA40882A true MA40882A (fr) 2017-10-04
MA40882B1 MA40882B1 (fr) 2020-05-29

Family

ID=54695680

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053242A MA53242A (fr) 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
MA40882A MA40882B1 (fr) 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053242A MA53242A (fr) 2014-11-14 2015-11-13 Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf

Country Status (29)

Country Link
US (6) US10392445B2 (fr)
EP (3) EP3489256B1 (fr)
JP (2) JP6873901B2 (fr)
KR (3) KR102877243B1 (fr)
CN (4) CN114634570B (fr)
AU (3) AU2015345024B2 (fr)
CL (2) CL2017001000A1 (fr)
CO (1) CO2017003212A2 (fr)
CR (1) CR20170194A (fr)
DK (2) DK3224275T3 (fr)
EA (1) EA037557B1 (fr)
ES (2) ES2788979T3 (fr)
HR (2) HRP20200679T1 (fr)
HU (2) HUE049982T2 (fr)
IL (2) IL282922B (fr)
LT (2) LT3489256T (fr)
MA (2) MA53242A (fr)
MX (2) MX380253B (fr)
MY (1) MY191428A (fr)
PE (2) PE20170896A1 (fr)
PH (1) PH12017500892B1 (fr)
PL (2) PL3224275T3 (fr)
PT (1) PT3224275T (fr)
RS (2) RS61870B1 (fr)
SG (1) SG11201703597TA (fr)
SI (2) SI3489256T1 (fr)
TW (2) TWI757803B (fr)
UA (1) UA125577C2 (fr)
WO (1) WO2016075278A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) * 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356405B1 (fr) * 2015-10-02 2026-07-08 F. Hoffmann-La Roche AG Anticorps anti-humain cd19 à affinité élevée
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
EP3356407B1 (fr) * 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-cd19xcd3
JP7044700B2 (ja) * 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
CA3004830A1 (fr) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition et methodes pour anticorps anti-tnfr2
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3243836A1 (fr) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
EP3455254B1 (fr) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison de ténascine
EP3243832A1 (fr) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1
JP7213180B2 (ja) 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
JP7125400B2 (ja) * 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CA3047070A1 (fr) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Molecules bispecifiques de liaison a l'antigene comprenant un clone 20h4.9 anti-4-1bb
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
WO2018151820A1 (fr) * 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Molécules multifonctionnelles comprenant un ligand trimérique et leurs utilisations
WO2018178076A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
WO2018178055A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CN110402255B (zh) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
CA3052532A1 (fr) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Anticorps bispecifiques se liant particulierement a pd1 et lag3
EP3615564A1 (fr) * 2017-04-24 2020-03-04 Alexion Pharmaceuticals, Inc. Protéines de fusion d'inhibiteur de cellules immunitaires d'anticorps
WO2018226887A1 (fr) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées
CN111246884A (zh) * 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3502140A1 (fr) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
CA3084398A1 (fr) * 2018-01-15 2019-07-18 I-Mab Biopharma Us Limited Domaines ck et ch1 modifies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
PL3765489T3 (pl) * 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
CR20200459A (es) * 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
IL280102B1 (en) * 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
CA3104780A1 (fr) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Proteine de fusion du variant de sirpalpha-4-1bbl et procedes d'utilisation associes
US11242396B2 (en) 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
JP2022535564A (ja) 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
CA3140668A1 (fr) * 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Compositions de ca2 et procedes de regulation ajustable
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
MX2021015823A (es) 2019-06-26 2022-02-03 Hoffmann La Roche Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
JP7675083B2 (ja) * 2020-01-09 2025-05-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規４－１ｂｂｌ三量体含有抗原結合分子
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021209050A1 (fr) * 2020-04-17 2021-10-21 Biocytogen Jiangsu Co., Ltd. Animal non humain génétiquement modifié avec le/les gènes tnfsf9 et/ou 4-1bb humain(s) ou chimérique(s)
WO2021229103A2 (fr) 2020-05-15 2021-11-18 Apogenix Ag Modulateurs immunitaires multi-spécifiques
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2022008688A1 (fr) 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Anticorps se liant à des cellules cancéreuses et ciblant ces cellules avec des radionucléides
TW202219067A (zh) * 2020-07-24 2022-05-16 瑞士商赫孚孟拉羅股份公司 用於表現抗體多聚體融合之方法
PE20240690A1 (es) 2021-01-12 2024-04-10 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
AU2022207624A1 (en) 2021-01-13 2023-07-13 F. Hoffmann-La Roche Ag Combination therapy
AU2022231874A1 (en) 2021-03-09 2023-07-27 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
WO2022243261A1 (fr) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Molécules de liaison à l'antigène cd40 agonistes ciblant cea
CN117396182A (zh) * 2021-05-21 2024-01-12 百济神州有限公司 抗cea和抗cd137多特异性抗体及其使用方法
BR112023025020A2 (pt) * 2021-06-01 2024-02-20 Janssen Biotech Inc Anticorpos anti-idiotípicos contra anticorpos anti-cd79b
EP4148067A1 (fr) * 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Procédé d'expression d'une fusion anticorps-multimère
JP2024540174A (ja) 2021-11-01 2024-10-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体および４－１ｂｂ（ｃｄ１３７）アゴニストを用いたがんの治療
WO2023088876A1 (fr) 2021-11-16 2023-05-25 Apogenix Ag Modulateurs immunitaires multi-spécifiques
WO2023088889A1 (fr) 2021-11-16 2023-05-25 Apogenix Ag Ligand cd137
EP4448560A1 (fr) 2021-12-14 2024-10-23 F. Hoffmann-La Roche AG Traitement du cancer à l'aide d'un anticorps bispécifique hla-a2/mage-a4 x cd3 et d'un agoniste de 4-1bb (cd137)
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN114426585B (zh) * 2022-02-15 2023-10-03 广东香雪干细胞再生医学科技有限公司 融合蛋白及其表达细胞株与应用
CN116462769A (zh) * 2022-04-02 2023-07-21 广东东阳光药业有限公司 一种嵌合受体及其应用
CN114805564B (zh) * 2022-06-10 2023-06-06 郑州大学 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用
EP4587122A1 (fr) 2022-09-15 2025-07-23 Avidicure IP B.V. Protéines de liaison à un antigène multispécifiques pour stimuler des cellules nk et utilisation associée
WO2024094741A1 (fr) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Polythérapie avec un anticorps bispécifique anti-cd19/anti-cd28
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
CN120826234A (zh) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
WO2024188966A1 (fr) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps bispécifique anti-hla-g/anti-cd3 et d'un agoniste de 4-1bb (cd137)
CN118894934A (zh) 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN119552258B (zh) 2023-09-01 2025-11-07 北京智仁美博生物科技有限公司 结合hla-a02/mage-a4复合体的多种抗体及其用途
CN119912577A (zh) 2023-10-31 2025-05-02 北京智仁美博生物科技有限公司 结合hla-a24/prame复合体的多种抗体及其用途
CN119930832A (zh) 2023-11-02 2025-05-06 北京智仁美博生物科技有限公司 结合HLA-A02/HBsAg复合体的多种抗体及其用途
CN121851173A (zh) 2023-11-30 2026-04-14 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025140212A1 (fr) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Agents de liaison multispécifiques comprenant des anticorps anti-protéine d'activation des fibroblastes (fap) et un ou plusieurs pièges à ligands monovalents et leurs utilisations
WO2025191136A1 (fr) 2024-03-15 2025-09-18 Avidicure Ip B.V. Mutéines de domaine extracellulaire de ligand 4-1 bb, protéines de fusion les comprenant et leurs utilisations
WO2025191139A1 (fr) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugués de protéines de liaison à l'antigène spécifiques de her2 et de cytokines
WO2025191133A1 (fr) 2024-03-15 2025-09-18 Avidicure Ip B.V. Mutéines d'il-21, protéines de fusion les comprenant et leurs utilisations
WO2026087747A1 (fr) 2024-10-24 2026-04-30 Avidicure Ip B.V. Protéines multispécifiques de liaison à l'antigène pour le ciblage de tumeurs de lymphocytes t γδ1 et leur utilisation
WO2026087748A1 (fr) 2024-10-24 2026-04-30 Avidicure Ip B.V. Protéines multispécifiques de liaison à l'antigène pour l'expansion de lymphocytes t γδ et leur utilisation

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (de) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Ohrring
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2307166A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
EP2311867A1 (fr) 2002-10-29 2011-04-20 Anaphore, Inc. Protéines à liaison trimérique pour cytokines trimériques
CA2515100A1 (fr) * 2003-02-06 2004-08-19 Micromet Ag Reponse de lymphocyte t durable
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2531238C (fr) 2003-07-04 2015-02-24 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU2013263717B2 (en) 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
EP1736482A1 (fr) 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Ligand recombinant trimeric de 4-1BB
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
EP2009022A1 (fr) 2007-06-26 2008-12-31 Apogenix GmbH Ligands trimériques avec activité améliorée (tenascine)
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
WO2010037395A2 (fr) * 2008-10-01 2010-04-08 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
PL2483310T3 (pl) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecyficzne przeciwciała agonistyczne dla receptora śmierci
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011147834A1 (fr) 2010-05-26 2011-12-01 Roche Glycart Ag Anticorps contre cd19 et utilisations associées
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
US8552024B2 (en) 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
JP6047142B2 (ja) 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
JP2013055204A (ja) 2011-09-02 2013-03-21 Toshiba Corp 半導体記憶装置
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
EP2948475A2 (fr) * 2013-01-23 2015-12-02 AbbVie Inc. Procédés et compositions pour la modulation du systéme immunitaire
CN110437337B (zh) * 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
JP6618463B2 (ja) 2013-05-07 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三量体型抗原結合分子
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
CN106456734A (zh) 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356407B1 (fr) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-cd19xcd3
EP3356405B1 (fr) 2015-10-02 2026-07-08 F. Hoffmann-La Roche AG Anticorps anti-humain cd19 à affinité élevée
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
CN108290958B (zh) 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
EP3231813A1 (fr) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Molécules de liaison d'antigène costimulantes trimères contenant un ligand de la famille du tnf
EP3455254B1 (fr) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison de ténascine
EP3243836A1 (fr) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
EP3243832A1 (fr) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1
EP3482170B1 (fr) 2016-07-08 2020-02-12 Roche Diagnostics GmbH Système d'automatisation de laboratoire et procédé permettant de pipetter un échantillon de laboratoire
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CA3047070A1 (fr) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Molecules bispecifiques de liaison a l'antigene comprenant un clone 20h4.9 anti-4-1bb
WO2018178076A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
WO2018178055A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
CN110402255B (zh) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
US11242396B2 (en) 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
CN113677403B (zh) 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
JP7675083B2 (ja) 2020-01-09 2025-05-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規４－１ｂｂｌ三量体含有抗原結合分子
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
PL3489256T3 (pl) 2021-08-23
EP3738609C0 (fr) 2025-06-18
CL2019003728A1 (es) 2020-07-17
CO2017003212A2 (es) 2017-09-20
IL251317B (en) 2021-05-31
HUE049982T2 (hu) 2020-11-30
RS61870B1 (sr) 2021-06-30
JP2018503356A (ja) 2018-02-08
TWI713474B (zh) 2020-12-21
BR112017009006A2 (pt) 2018-04-10
MX2020012798A (es) 2022-04-07
EP3738609B1 (fr) 2025-06-18
US20200247904A1 (en) 2020-08-06
MX391388B (es) 2025-03-21
US10392445B2 (en) 2019-08-27
NZ730933A (en) 2024-02-23
US20220259327A1 (en) 2022-08-18
EA201791057A1 (ru) 2017-10-31
DK3224275T3 (da) 2020-05-04
EA037557B1 (ru) 2021-04-14
JP7184938B2 (ja) 2022-12-06
EP3489256A1 (fr) 2019-05-29
HK1255482A1 (zh) 2019-08-16
JP6873901B2 (ja) 2021-05-19
KR20250158074A (ko) 2025-11-05
US20190382507A1 (en) 2019-12-19
AU2020264337A1 (en) 2021-01-28
AU2015345024B2 (en) 2020-10-15
MA40882B1 (fr) 2020-05-29
EP3224275B1 (fr) 2020-03-04
CN114634570A (zh) 2022-06-17
MX2017006250A (es) 2017-11-17
CN113372434B (zh) 2024-06-04
PH12017500892B1 (en) 2023-08-18
AU2020264337B2 (en) 2021-12-02
CN108064237B (zh) 2022-02-11
SI3489256T1 (sl) 2021-08-31
AU2022201144A1 (en) 2022-03-17
KR20170085552A (ko) 2017-07-24
HUE054122T2 (hu) 2021-08-30
EP3489256B1 (fr) 2021-03-17
MY191428A (en) 2022-06-27
IL282922B (en) 2022-08-01
CL2017001000A1 (es) 2018-01-12
IL282922A (en) 2021-06-30
PE20221909A1 (es) 2022-12-23
EP3738609A1 (fr) 2020-11-18
MA53242A (fr) 2021-06-23
JP2021097674A (ja) 2021-07-01
SG11201703597TA (en) 2017-06-29
DK3489256T3 (da) 2021-05-25
US20250101135A1 (en) 2025-03-27
KR102588377B1 (ko) 2023-10-12
PT3224275T (pt) 2020-05-04
AU2022201144B2 (en) 2025-03-06
ES2788979T3 (es) 2020-10-23
CN120574325A (zh) 2025-09-02
KR20230146133A (ko) 2023-10-18
HRP20200679T1 (hr) 2020-07-24
PH12017500892A1 (en) 2017-11-06
NZ767672A (en) 2024-02-23
PL3224275T3 (pl) 2020-09-07
ES2871045T3 (es) 2021-10-28
WO2016075278A1 (fr) 2016-05-19
US20220259326A1 (en) 2022-08-18
SI3224275T1 (sl) 2020-07-31
CN113372434A (zh) 2021-09-10
US20160200833A1 (en) 2016-07-14
CN114634570B (zh) 2025-05-06
RS60201B1 (sr) 2020-06-30
US11306154B2 (en) 2022-04-19
PE20170896A1 (es) 2017-07-12
NZ767674A (en) 2024-07-05
US12441812B2 (en) 2025-10-14
AU2015345024A1 (en) 2017-04-20
TW202041527A (zh) 2020-11-16
LT3489256T (lt) 2021-06-10
US11267903B2 (en) 2022-03-08
HRP20210739T1 (hr) 2021-06-25
CN108064237A (zh) 2018-05-22
TWI757803B (zh) 2022-03-11
EP3224275A1 (fr) 2017-10-04
CA2963718A1 (fr) 2016-05-19
CR20170194A (es) 2017-07-10
TW201629094A (zh) 2016-08-16
LT3224275T (lt) 2020-05-25
KR102877243B1 (ko) 2025-10-29
MX380253B (es) 2025-03-12
IL251317A0 (en) 2017-05-29
UA125577C2 (uk) 2022-04-27

Similar Documents

Publication Publication Date Title
MA40882B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
PH12018502367A1 (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
MA40801B2 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
MX2013015324A (es) Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos.
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
MA38797A1 (fr) Protéine de fusion thérapeutique
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
CY1120803T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
MX2018005831A (es) Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
HK1258507A1 (zh) 改进的p2x7受体结合剂和包含其的多肽
DE602006020333D1 (de) Multimere fc-rezeptor-polypeptide
MX2021004684A (es) Anticuerpos especificos para apoj glucosilada y usos de los mismos.
MA47671B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
WO2017089781A3 (fr) Peptides
MA38497B1 (fr) Polypeptides d'il-22 et protéines de fusion fc il-22 et leurs procédés d'utilisation
TH1801005983A (th) นีโอแอนติเจน และวิธีของการใช้สิ่งเหล่านั้น